Strong year-to-date and Q3 performance drives upgrade to full-year guidance

For media and investors only

Full results announcement PDF

Download the Q3 2023 results announcement

Q3 2023 results announcement (PDF, 804.7KB)

Broad-based execution drives further sales and earnings growth

- Total Q3 2023 sales +10% and +16% ex COVID

- Vaccines sales +33%, +34% ex COVID. Shingrix £0.8 billion +15%, Arexvy sales £0.7 billion

- Specialty Medicines sales -1%, +17% ex COVID with HIV +15%

- General Medicines sales -2% with impact of generic competition to older products, in part offset by Trelegy +23%

- Total operating profit and Total continuing EPS reflects strong growth in the quarter and year to date with lower charges for contingent consideration liabilities remeasurement

- Adjusted operating profit +15% and Adjusted EPS +17% reflects strong execution, resilient growth and higher royalty income in part offset by increased investment in R&D, new product launches and a seven percentage point operating profit reduction from lower COVID-19 solutions sales

Q3 2023 Year to Date £m % AER % CER £m % AER % CER Turnover 8,147 4 10 22,276 1 2 Turnover ex COVID 8,146 10 16 22,102 12 13 Total operating profit 1,949 64 83 6,172 35 39 Total continuing EPS 36.1p 92 >100 113.0p 54 59 Adjusted operating profit 2,772 6 15 7,034 7 10 Adjusted operating margin % 34.0% 0.8ppts 1.7ppts 31.6% 1.7ppts 2.2ppts Adjusted EPS 50.4p 7 17 126.2p 11 14 Cash generated from operations 2,508 32 4,415 (24)

R&D delivery underpins longer-term growth outlook

- Arexvy approved in Japan as country’s first RSV vaccine for older adults; positive preliminary phase III data in adults aged 50-59 presented at ACIP and support regulatory filings

- New Shingrix data demonstrates 100% efficacy in preventing shingles in adults aged 50+ in China; copromotion partnership in China with Zhifei announced, set to begin in 2024

- Apretude long-acting treatment approved for HIV prevention in EU; clinical development plans advancing for innovative long-acting treatment and prevention regimens with data anticipated in 2024

- Ojjaara approved by US FDA as first and only line agnostic treatment for myelofibrosis patients with anaemia

- Jemperli plus chemotherapy approved in US as new frontline treatment for endometrial cancer

- Agreement to acquire worldwide rights to Janssen’s JNJ-3989, which may have potential to further increase functional cure rates of bepirovirsen in chronic hepatitis B treatment

2023 guidance upgrade, Q3 2023 dividend of 14p declared, 56.5p expected for full year

- Turnover to increase 12 to 13% (from 8 to 10%)

- Adjusted operating profit growth 13 to 15% (from 11 to 13%)

- Adjusted EPS growth 17 to 20% (from 14 to 17%)

Emma Walmsley, Chief Executive Officer, GSK:

GSK is delivering strong and sustained performance momentum, with another quarter of double-digit sales and earnings growth. Competitive performance was broadly based but benefitted particularly from the outstanding US launch of Arexvy, the world’s first RSV vaccine. Our excellent execution supports an upgrade to our full-year 2023 guidance and we have clear momentum as we look ahead to deliver our 2026 outlooks. GSK’s longer-term outlook also continues to strengthen, with progress in our vaccines pipeline, the development of our ultra long-acting HIV portfolio and significant new prospects in respiratory.

Assumptions and cautionary statement regarding forward-looking statements

The Group’s management believes that the assumptions outlined above are reasonable, and that the guidance, outlooks, ambitions and expectations described in this report are achievable based on those assumptions. However, given the forward-looking nature of these guidance, outlooks, ambitions and expectations, they are subject to greater uncertainty, including potential material impacts if the above assumptions are not realised, and other material impacts related to foreign exchange fluctuations, macro-economic activity, the impact of outbreaks, epidemics or pandemics, changes in legislation, regulation, government actions or intellectual property protection, product development and approvals, actions by our competitors, and other risks inherent to the industries in which we operate.

This document contains statements that are, or may be deemed to be, “forward-looking statements”. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulation, the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The reader should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the SEC. All readers, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statements in this Q3 2023 earnings release and the 2022 Annual Report.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this document, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk Factors’ in the Group’s Annual Report on Form 20-F for 2022. Any forward looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this report.